BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 35163234)

  • 1. Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods.
    Kulkarni AM; Kumar V; Parate S; Lee G; Yoon S; Lee KW
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations.
    Du Z; Tu G; Gong Y; Fu X; Wu Q; Long G
    Molecules; 2024 Mar; 29(6):. PubMed ID: 38542866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of Novel PDEδ Inhibitor Based on Pharmacophore and Molecular Docking against KRAS Mutant in Colorectal Cancer.
    Mouhcine M; Kadil Y; Rahmoune I; Filali H
    Curr Drug Discov Technol; 2023; 20(4):e160423215830. PubMed ID: 37066770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Potential Inhibitors Targeting GTPase-Kirsten RAt Sarcoma Virus (K-Ras) Driven Cancers via E-Pharmacophore-Based Virtual Screening and Drug Repurposing Approach.
    Kumar S U; Varghese RP; Preethi VA; Doss CGP; Zayed H
    Front Biosci (Landmark Ed); 2023 Nov; 28(11):288. PubMed ID: 38062837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Silico Prediction of New Inhibitors for Kirsten Rat Sarcoma G12D Cancer Drug Target Using Machine Learning-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulation Approaches.
    Ajmal A; Danial M; Zulfat M; Numan M; Zakir S; Hayat C; Alabbosh KF; Zaki MEA; Ali A; Wei D
    Pharmaceuticals (Basel); 2024 Apr; 17(5):. PubMed ID: 38794122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
    Islam MA; Pillay TS
    J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacophore-based virtual screening approach for identification of potent natural modulatory compounds of human Toll-like receptor 7.
    Gupta CL; Babu Khan M; Ampasala DR; Akhtar S; Dwivedi UN; Bajpai P
    J Biomol Struct Dyn; 2019 Nov; 37(18):4721-4736. PubMed ID: 30661449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of selective dengue virus inhibitors using combination of molecular fingerprint-based virtual screening protocols, structure-based pharmacophore model development, molecular dynamics simulations and in vitro studies.
    Mirza SB; Lee RCH; Chu JJH; Salmas RE; Mavromoustakos T; Durdagi S
    J Mol Graph Model; 2018 Jan; 79():88-102. PubMed ID: 29156382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New lead compounds identification against KRas mediated cancers through pharmacophore-based virtual screening and in vitro assays.
    Ghufran M; Rehman AU; Ayaz M; Ul-Haq Z; Uddin R; Azam SS; Wadood A
    J Biomol Struct Dyn; 2023; 41(16):8053-8067. PubMed ID: 36184737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel leads as potent inhibitors of HDAC3 using ligand-based pharmacophore modeling and MD simulation.
    Kumbhar N; Nimal S; Barale S; Kamble S; Bavi R; Sonawane K; Gacche R
    Sci Rep; 2022 Feb; 12(1):1712. PubMed ID: 35110603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. K-Ras
    Feng H; Zhang Y; Bos PH; Chambers JM; Dupont MM; Stockwell BR
    Biochemistry; 2019 May; 58(21):2542-2554. PubMed ID: 31042025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel Imidazo[1,2-a]pyridine derivative modulates active KRAS
    Ali Y; Khan AA; Alanazi AM; Fatima S; Kozmon S
    Int J Biol Macromol; 2024 Jun; 270(Pt 2):132477. PubMed ID: 38772459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishing the Role of Iridoids as Potential Kirsten Rat Sarcoma Viral Oncogene Homolog G12C Inhibitors Using Molecular Docking; Molecular Docking Simulation; Molecular Mechanics Poisson-Boltzmann Surface Area; Frontier Molecular Orbital Theory; Molecular Electrostatic Potential; and Absorption, Distribution, Metabolism, Excretion, and Toxicity Analysis.
    Alamri MA; Alawam AS; Alshahrani MM; Kawsar SMA; Prinsa ; Saha S
    Molecules; 2023 Jun; 28(13):. PubMed ID: 37446713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacophore-based virtual screening, molecular docking and molecular dynamics studies for the discovery of novel neuraminidase inhibitors.
    Lotfi B; Mebarka O; Khan SU; Htar TT
    J Biomol Struct Dyn; 2024 Jul; 42(10):5308-5320. PubMed ID: 37334701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacophore development, drug-likeness analysis, molecular docking, and molecular dynamics simulations for identification of new CK2 inhibitors.
    Hammad S; Bouaziz-Terrachet S; Meghnem R; Meziane D
    J Mol Model; 2020 May; 26(6):160. PubMed ID: 32472293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
    Iqbal S; Anantha Krishnan D; Gunasekaran K
    J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Camptothecin Based Topoisomerase I Inhibitors: Identification Using an Atom Based 3D-QSAR, Pharmacophore Modeling, Virtual Screening and Molecular Docking Approach.
    Dev S; Dhaneshwar SR; Mathew B
    Comb Chem High Throughput Screen; 2016; 19(9):752-763. PubMed ID: 27515040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel peptide inhibitors for oncogenic KRAS G12D as therapeutic options using mutagenesis-based remodeling and MD simulations.
    Samad A; Khurshid B; Mahmood A; Rehman AU; Khalid A; Abdalla AN; Algarni AS; Wadood A
    J Biomol Struct Dyn; 2023; 41(22):13425-13437. PubMed ID: 37010994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
    Sharma A; Thelma BK
    J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational Simulations Identified Two Candidate Inhibitors of Cdk5/p25 to Abrogate Tau-associated Neurological Disorders.
    Zeb A; Son M; Yoon S; Kim JH; Park SJ; Lee KW
    Comput Struct Biotechnol J; 2019; 17():579-590. PubMed ID: 31073393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.